SELECTED AGENDA TOPICS - Bioavailability/Bioequivalence Site Evaluation During the Pandemic
- Pre-ANDA Program Update and Tips for Success
- Learnings and Insight from Records Requests under § 704(a)(4) of the FD&C Act in lieu of
Pre-Approval Inspections - Mid-Review Cycle Meeting Overview
- Building a Better Sterility Assurance Application
- Premarket Review of Expedited Serious Adverse Event Reports of BA/BE Studies
- And more...
This event offers practical advice, case studies, and a deep dive into the Abbreviated New Drug Application (ANDA) review process. Presentations will focus on various aspects from pre-ANDA, drug development, post-marketing and global generic drug affairs program support for the generic drug program. | | KEYNOTE Sally Choe, Ph.D. Director, Office of Generic Drugs (OGD), Center for Drug Evaluation and Research (CDER) | |
No comments:
Post a Comment